Earnings Call Summary | Nanobiotix(NBTX.US) Q4 2023 Earnings Conference
The following is a summary of the Nanobiotix S.A. (NBTX) Q4 2023 Earnings Call Transcript:Financial Performance:Nanobiotix entered into a $2.5 billion license agreement with Johnson Pharmaceutical in
Nanobiotix S.A. (NBTX) Q4 2023 Earnings Call Transcript
Good day and welcome to the Nanobiotix Business Update and Full-Year 2023 Financial Results Conference Call. At this time all participants’ are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. Please be advised that today's conference is being recorded.
Nanobiotix's Revenue at Risk: The High Stakes of Sole Dependence on Janssen Partnership
Nanobiotix FY 2023 GAAP EPS $(1.17) Beats $(1.66) Estimate, Sales $39.323M Beat $13.680M Estimate
Nanobiotix (NASDAQ:NBTX) reported quarterly losses of $(1.17) per share which beat the analyst consensus estimate of $(1.66) by 29.52 percent. This is a 32.37 percent increase over losses of $(1.73) p
Nanobiotix Sa ADR Reports Promising 2023 Progress
Nanobiotix 2023 Rev EUR36.2M >NANO.FR
Nanobiotix 2023 Rev EUR36.2M >NANO.FR
Press Release: NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results
NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results -- Global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV ("Janssen"
Nanobiotix Sa ADR Sets Q4 and Full Year Results Date
NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024
PARIS and CAMBRIDGE, Mass., April 17, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients
CarMax Reports Downbeat Earnings, Joins Lovesac And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling over 150 points on Thursday. Shares of CarMax, Inc. (NYSE:KMX) fell sharply in today's pre-market trading after the company r
Nanobiotix Sa ADR Updates Share Capital Info
Nanobiotix Completes Dose Escalation Segment of Phase 1 Study Targeting Non-Small Cell Lung Cancer
Nanobiotix (NBTX) said late Tuesday it completed the dose escalation part of a phase 1 study evaluating potential first-in-class radioenhancer NBTXR3 for patients with non-small cell lung cancer. The
Nanobiotix Announces Completion Of Phase 1 Dose Escalation And NBTXR3 Recommended Phase 2 Dose For The Treatment Of Inoperable, Recurrent Lung Cancer In Patients Amenable To Re-Irradiation
Established recommended Phase 2 dose of NBTXR3 for the treatment of patients with inoperable, recurrent non-small cell lung cancer ("NSCLC") who have previously received definitive radiation therapyCo
Logitech, B. Riley Financial And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were mostly higher this morning, with the Nasdaq futures gaining by around 100 points on Monday. Shares of Logitech International S.A. (NASDAQ:LOGI) fell in today's pre-market trad
EQT, Genie Energy And Other Big Stocks Moving Lower On Monday
U.S. stocks were lower, with the Dow Jones index falling more than 150 points on Monday.
Nanobiotix to Present at Upcoming Investor Conferences in March
PARIS and CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients
Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference
PARIS and CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients
Baillie Gifford Bolsters Stake in Nanobiotix SA
General Motors Posts Upbeat Earnings, Joins Corning, HCA Healthcare And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded slightly lower, with the Dow Jones falling around 20 points on Tuesday. Shares of General Motors Company (NYSE:GM) rose sharply during Tuesday's session after the company reported
UBS Keeps Their Buy Rating on Nanobiotix (NBTX)
No Data